Clinical experience with the etanercept biosimilar SB4 in psoriatic patients
| Autor: | L. Lazzeri, Federica Ricceri, Leonardo Pescitelli, Francesca Prignano, A. Di Cesare, Lara Tripo |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
musculoskeletal diseases
Adult Male medicine.medical_specialty Pharmaceutical Science Pharmacy Toxicology 030226 pharmacology & pharmacy Etanercept Cohort Studies 03 medical and health sciences Psoriatic arthritis 0302 clinical medicine Internal medicine Psoriasis medicine Humans Pharmacology (medical) 030212 general & internal medicine skin and connective tissue diseases Biosimilar Pharmaceuticals Aged Pharmacology business.industry Drug Substitution Moderate to severe psoriasis Anti-Inflammatory Agents Non-Steroidal Biosimilar Middle Aged medicine.disease Cohort Female Previously treated business Immunosuppressive Agents medicine.drug |
| Zdroj: | International journal of clinical pharmacy. 41(1) |
| ISSN: | 2210-7711 |
| Popis: | Background After the expiry of the patent of reference etanercept, several biosimilars have been developed, including SB4. Objective To study safety and efficacy of SB4 in psoriatic patients previously treated with etanercept and in the etanercept naive ones. Method Patients affected by moderate to severe psoriasis and/or psoriatic arthritis attending the Psoriasis Center of Florence University, treated with SB4 were enrolled in the study. Patients were divided in two cohorts. Cohort 1 included 32 patients who were switched from previous etanercept, cohort 2 included 12 patients who were naive to etanercept. Results Evaluation of the efficacy of SB4 in cohort 1 patients revealed rates of clinical remission (defined as both PASI and/or DAS28 increase |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink